Latest News and Press Releases

PRESS RELEASE AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE...

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L’ACHÈVEMENT DE L’ÉTAPE 3 DE LA PHASE 1, ÉVALUANT LA COMBINAISON D’AB8939 ET DU VÉNÉTOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN...

AmMax Bio, clinical stage targeted oncology ADC company, names biopharmaceutical Executive Travis Read as President and COO.

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – ...

EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and...

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with...

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.

Entries are now open for the inaugural Future Digital Awards for Identity & Security 2026. Apply via the entry form on the website. Entry is free.

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- SEON, the AI Command Center for Fraud Prevention and AML Compliance, today announced the appointment of Sagnik Nandy, Chief Technology Officer and...